The median age of patients who underwent tertiary treatment (n = 22) for prostate cancer was 77.5 (75.0–85.0) years and the median PSA was 146.2 (7.8–2380.0) ng/mL; 90.9% of patients who underwent tertiary treatment had GSs ≥8 and 59.1% had metastatic prostate cancer. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.